MedX Health Corp. Announces Proposed Private Placement to Raise $203,000


MISSISSAUGA, ONTARIO--(Marketwired - Dec. 20, 2013) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announces that it has entered into private placement agreements with accredited investors to raise a total of $203,000 by issuance of a total of 2,030,000 Units at $0.10 per unit. Each Unit comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at the price of $0.20 during the period expiring December 31, 2014. Closing of the Placement is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.

MedX presently has 57,714,657 common shares issued and outstanding.

About MedX

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX's products include SIMSYS™ and MoleMate™, which are approved by Health Canada, and available to Canadian physicians and dermatologists, are FDA approved for use in the USA and are currently under review for CE approval for use in Europe, the UK, and Australia, as an optical biopsy that uses patented technology featuring a hand-held scanner device designed for clinical use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images in real-time for physicians and dermatologists to evaluate all types of moles or lesions within seconds. For more information log onto: www.simsys-molemate.com. For a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information:

MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com